ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C
- Conditions
- chronic hepatitis C
- Registration Number
- JPRN-UMIN000023086
- Lead Sponsor
- Hiroshima University
- Brief Summary
Overall, SVR12 was achieved in 231 (94.7%) patients, based on intention to treat analysis. During the therapy, reduction of hemoglobin levels was significantly greater in ITPA genotype CC patients than CA/AA patients. Therefore, the cumulative proportion of patients with RBV dose reduction was significantly higher and total dose of RBV was significantly lower in patients with CC genotype compared to CA/AA genotypes. SVR12 rates were similar between ITPA genotype CC and CA/AA (94.7% and 94.4%, respectively, P=0.933). Multivariate logistic regression analysis identified FIB4 index <3.25 (OR, 9.388 for >3.25; P=0.005) and low body weight (OR, 1.059, for high body weight; P=0.017) as independent predictors for SVR12.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 500
Not provided
Patients with decompensated cirrhosis
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method sustained virological response (negative for serum HCV RNA at 24 weeks after the treatment)
- Secondary Outcome Measures
Name Time Method Hemoglobin during the treatment period